BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alì G, Bruno R, Poma AM, Affinito O, Monticelli A, Piaggi P, Ricciardi S, Lucchi M, Melfi F, Chella A, Cocozza S, Fontanini G. Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas. Sci Rep 2019;9:3536. [PMID: 30837581 DOI: 10.1038/s41598-019-40016-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mirhadi S, Tam S, Li Q, Moghal N, Pham NA, Tong J, Golbourn BJ, Krieger JR, Taylor P, Li M, Weiss J, Martins-Filho SN, Raghavan V, Mamatjan Y, Khan AA, Cabanero M, Sakashita S, Huo K, Agnihotri S, Ishizawa K, Waddell TK, Zadeh G, Yasufuku K, Liu G, Shepherd FA, Moran MF, Tsao MS. Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. Nat Commun 2022;13:1811. [PMID: 35383171 DOI: 10.1038/s41467-022-29444-9] [Reference Citation Analysis]
2 Al-Dherasi A, Huang QT, Liao Y, Al-Mosaib S, Hua R, Wang Y, Yu Y, Zhang Y, Zhang X, Huang C, Mousa H, Ge D, Sufiyan S, Bai W, Liu R, Shao Y, Li Y, Zhang J, Shi L, Lv D, Li Z, Liu Q. A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD). Cancer Cell Int 2021;21:294. [PMID: 34092242 DOI: 10.1186/s12935-021-01975-z] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
3 Chen M, Yang Q, Xu Z, Luo B, Li F, Yu Y, Sun J. Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database. Front Oncol 2021;11:630885. [PMID: 34136380 DOI: 10.3389/fonc.2021.630885] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Yang Z, Shen Y, Jiang J, Liu Z, Mu C. Transformation of Two Cases of Lung Adenocarcinoma into Pulmonary Sarcomatoid Carcinoma following Treatment. Can Respir J 2021;2021:6661772. [PMID: 33488884 DOI: 10.1155/2021/6661772] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Chen P, Yu M, Zhang JL, Chen WY, Zhu L, Song Y, Jiang CY, Zhang S. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report. World J Clin Cases 2020; 8(13): 2876-2884 [PMID: 32742998 DOI: 10.12998/wjcc.v8.i13.2876] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Liu T, Zhao X, Zheng X, Zheng Y, Dong X, Zhao N, Liao S, Sun B. The EMT transcription factor, Twist1, as a novel therapeutic target for pulmonary sarcomatoid carcinomas. Int J Oncol 2020;56:750-60. [PMID: 32124963 DOI: 10.3892/ijo.2020.4972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Baldovini C, Rossi G, Ciarrocchi A. Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma. Lung Cancer (Auckl) 2019;10:131-49. [PMID: 31824199 DOI: 10.2147/LCTT.S186779] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
8 Schueler J, Tschuch C, Klingner K, Bug D, Peille AL, de Koning L, Oswald E, Klett H, Sommergruber W. Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization. Cells 2019;8:E740. [PMID: 31323891 DOI: 10.3390/cells8070740] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]